Care of pediatric cancers in the developing world: Should this be a societal priority? Maurie Markman Editor’s Commentary Pages: 81 - 82
Epidermal growth factor receptor expression in renal cell carcinoma: Rationale for therapy with sidling blockade Ronald M. Bukowski Clinical Trials Report Pages: 87 - 89
Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds Matthew M. CooneyJose OrtizScot C. Remick OriginalPaper Pages: 90 - 95
Clinical experience with monoclonal antibodies to epidermal growth factor receptor Emiliano CalvoEric K. Rowinsky OriginalPaper Pages: 96 - 103
Immunotherapy for human cancer using heat shock protein-peptide complexes Pramod K. Srivastava OriginalPaper Pages: 104 - 108
G250: A carbonic anhydrase IX monoclonal antibody John S. LamAllan J. PantuckRobert A. Figlin OriginalPaper Pages: 109 - 115
Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents Apurva A. DesaiWalter M. Stadler OriginalPaper Pages: 116 - 122
Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor Emiliano CalvoEric K. Rowinsky OriginalPaper Pages: 123 - 128
Intensity-modulated radiotherapy: Is xerostomia still prevalent? Mark S. ChambersAdam S. GardenRandal S. Weber OriginalPaper Pages: 131 - 136
Functional imaging in head and neck cancer David I. KutlerRichard J. WongDennis H. Kraus OriginalPaper Pages: 137 - 144
Prevention of head and neck cancer Terry A. DayAngela ChiJames R. Hebert OriginalPaper Pages: 145 - 153
High-risk non-melanoma skin cancer of the head and neck Stephen Y. LaiRandal S. Weber OriginalPaper Pages: 154 - 158
